Allogene Current Deferred Revenue from 2010 to 2024
| ALLO Stock | USD 2.41 0.03 1.23% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 86 K | Current Value 81.7 K | Quarterly Volatility 17.7 M |
Check Allogene Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Allogene Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 20.7 M, Selling General Administrative of 61.1 M or Total Revenue of 90.2 K, as well as many indicators such as Price To Sales Ratio of 5.6 K, Dividend Yield of 0.0 or PTB Ratio of 0.93. Allogene financial statements analysis is a perfect complement when working with Allogene Therapeutics Valuation or Volatility modules.
Allogene | Current Deferred Revenue |
Latest Allogene Therapeutics' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Allogene Therapeutics over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Allogene Therapeutics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Allogene Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Allogene Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 28,692,513 | |
| Geometric Mean | 9,879,061 | |
| Coefficient Of Variation | 61.62 | |
| Mean Deviation | 15,105,914 | |
| Median | 38,992,000 | |
| Standard Deviation | 17,680,110 | |
| Sample Variance | 312.6T | |
| Range | 38.9M | |
| R-Value | (0.77) | |
| Mean Square Error | 137.9T | |
| R-Squared | 0.59 | |
| Significance | 0.0008 | |
| Slope | (3,037,925) | |
| Total Sum of Squares | 4376.2T |
Allogene Current Deferred Revenue History
About Allogene Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Allogene Therapeutics income statement, its balance sheet, and the statement of cash flows. Allogene Therapeutics investors use historical funamental indicators, such as Allogene Therapeutics's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Allogene Therapeutics investors may use each financial statement separately, they are all related. The changes in Allogene Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Allogene Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Allogene Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Allogene Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 86 K | 81.7 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Allogene Stock
When determining whether Allogene Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Allogene Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Allogene Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Allogene Therapeutics Stock:Check out the analysis of Allogene Therapeutics Correlation against competitors. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.27) | Return On Assets (0.27) | Return On Equity (0.55) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.